ON THE COVER:
The effect of withholding angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEi/ARBs) before noncardiac surgery is unknown. In this issue of Anesthesiology, Roshanov et al. analyzed data from the Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) Prospective Cohort study to examine the relationship between withholding ACEi/ARBs and outcomes. Withholding ACEi/ARBs before major noncardiac surgery was associated with a lower risk of death and postoperative vascular events. In an accompanying Editorial View, London discusses the limitations of our current understanding and emphasizes that a randomized trial is needed to confirm these findings.
Roshanov et al.: Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort, p. 16
London: Preoperative Administration of Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers: Do We Have Enough “VISION” to Stop It? p. 1